Oligonucleotides
Optimising the development and scale-up of oligonucleotide-based therapeutics.
Get to market faster with CPI
At CPI, we accelerate the development, optimisation, and scale-up of oligonucleotide therapies, enabling efficient and cost-effective production for RNA therapeutics, antisense oligonucleotides, siRNA, oligo-conjugates and related applications.
With expertise in synthesis, purification, formulation, and analytical characterisation, we help you streamline oligonucleotide manufacturing while ensuring stability, scalability, and clinical readiness. Our state-of-the-art infrastructure and GMP-ready facilities support preclinical and clinical development, helping you bring next-generation therapies to market faster.
Oligonucleotides
Optimising the development and scale-up of oligonucleotide-based therapeutics.
Get to market faster with CPI
At CPI, we accelerate the development, optimisation, and scale-up of oligonucleotide therapies, enabling efficient and cost-effective production for RNA therapeutics, antisense oligonucleotides, siRNA, oligo-conjugates and related applications.
With expertise in synthesis, purification, formulation, and analytical characterisation, we help you streamline oligonucleotide manufacturing while ensuring stability, scalability, and clinical readiness. Our state-of-the-art infrastructure and GMP-ready facilities support preclinical and clinical development, helping you bring next-generation therapies to market faster.
Oligonucleotides
Optimising the development and scale-up of oligonucleotide-based therapeutics.
Get to market faster with CPI
At CPI, we accelerate the development, optimisation, and scale-up of oligonucleotide therapies, enabling efficient and cost-effective production for RNA therapeutics, antisense oligonucleotides, siRNA, oligo-conjugates and related applications.
With expertise in synthesis, purification, formulation, and analytical characterisation, we help you streamline oligonucleotide manufacturing while ensuring stability, scalability, and clinical readiness. Our state-of-the-art infrastructure and GMP-ready facilities support preclinical and clinical development, helping you bring next-generation therapies to market faster.
What we offer
Whether you need technical expertise, lab-based development, process optimisation, or regulatory guidance, our tailored approach ensures you have the right support at every stage.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
Oligonucleotide process development and scale-up
Optimise and scale your oligonucleotide therapeutics with CPI’s expertise:
Synthesis of DNA, RNA, and modified oligonucleotides.
Optimisation of reaction conditions for enhanced yield and purity.
Enzymatic and chemical oligonucleotide synthesis technologies.
Downstream purification via anion exchange chromatography and ultrafiltration.
Techno-economic evaluation of novel synthesis and purification strategies
Process development from milligram to gram-scale.
Process equipment including Cytiva’s OligoSyntTM, Äkta FluxTM, and Äkta PureTM.
These capabilities ensure cost-effective, scalable oligonucleotide manufacturing.
Oligonucleotide analytical development and characterisation
Ensure the quality, integrity, and stability of your oligonucleotide-based therapeutics with CPI’s analytical expertise:
Purity analysis in our on-site QC lab with high resolution LC-MS.
LC-MS method development and validation.
Thermo Fisher Scientific Vanquish HPLC coupled to Exploris 120 or ISQ mass spectrometers for accurate molecular weight, purity and sequence information
Additional test methods including UV-Vis spectrometer, Raman, GC and Endotoxin analysis.
Method development validation.
Supporting information for regulatory submissions.
These capabilities ensure compliance with stringent quality and regulatory standards.
GMP supply for preclinical and clinical studies
Secure high-quality oligonucleotides for early-stage development:
Scalable oligonucleotide production for gram scale (1–30 mmol) for pre-clinical studies.
Clinical-grade oligonucleotide synthesis at kg scale (10–100 mmol).
Cytiva’s OligoPilotTM, ÄktaprocessTM and UnifluxTM with supporting process equipment.
Electronic batch record and dedicated process transfer support
Seamless integration with supply chain partners for formulation development and drug product manufacturing.
Evaluation and integration of new process technologies including biocatalytic, liquid phase and fragment-based synthesis.
Full package of quality assurance services, including ‘Qualified Person’.
These capabilities support regulatory compliance and enable smooth progression from discovery to clinical trials.
What we offer
Whether you need technical expertise, lab-based development, process optimisation, or regulatory guidance, our tailored approach ensures you have the right support at every stage.
Oligonucleotide process development and scale-up
Optimise and scale your oligonucleotide therapeutics with CPI’s expertise:
Synthesis of DNA, RNA, and modified oligonucleotides.
Optimisation of reaction conditions for enhanced yield and purity.
Enzymatic and chemical oligonucleotide synthesis technologies.
Downstream purification via anion exchange chromatography and ultrafiltration.
Techno-economic evaluation of novel synthesis and purification strategies
Process development from milligram to gram-scale.
Process equipment including Cytiva’s OligoSyntTM, Äkta FluxTM, and Äkta PureTM.
These capabilities ensure cost-effective, scalable oligonucleotide manufacturing.
Oligonucleotide analytical development and characterisation
Ensure the quality, integrity, and stability of your oligonucleotide-based therapeutics with CPI’s analytical expertise:
Purity analysis in our on-site QC lab with high resolution LC-MS.
LC-MS method development and validation.
Thermo Fisher Scientific Vanquish HPLC coupled to Exploris 120 or ISQ mass spectrometers for accurate molecular weight, purity and sequence information
Additional test methods including UV-Vis spectrometer, Raman, GC and Endotoxin analysis.
Method development validation.
Supporting information for regulatory submissions.
These capabilities ensure compliance with stringent quality and regulatory standards.
GMP supply for preclinical and clinical studies
Secure high-quality oligonucleotides for early-stage development:
Scalable oligonucleotide production for gram scale (1–30 mmol) for pre-clinical studies.
Clinical-grade oligonucleotide synthesis at kg scale (10–100 mmol).
Cytiva’s OligoPilotTM, ÄktaprocessTM and UnifluxTM with supporting process equipment.
Electronic batch record and dedicated process transfer support
Seamless integration with supply chain partners for formulation development and drug product manufacturing.
Evaluation and integration of new process technologies including biocatalytic, liquid phase and fragment-based synthesis.
Full package of quality assurance services, including ‘Qualified Person’.
These capabilities support regulatory compliance and enable smooth progression from discovery to clinical trials.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
What we offer
Whether you need technical expertise, lab-based development, process optimisation, or regulatory guidance, our tailored approach ensures you have the right support at every stage.
Oligonucleotide process development and scale-up
Optimise and scale your oligonucleotide therapeutics with CPI’s expertise:
Synthesis of DNA, RNA, and modified oligonucleotides.
Optimisation of reaction conditions for enhanced yield and purity.
Enzymatic and chemical oligonucleotide synthesis technologies.
Downstream purification via anion exchange chromatography and ultrafiltration.
Techno-economic evaluation of novel synthesis and purification strategies
Process development from milligram to gram-scale.
Process equipment including Cytiva’s OligoSyntTM, Äkta FluxTM, and Äkta PureTM.
These capabilities ensure cost-effective, scalable oligonucleotide manufacturing.
Oligonucleotide analytical development and characterisation
Ensure the quality, integrity, and stability of your oligonucleotide-based therapeutics with CPI’s analytical expertise:
Purity analysis in our on-site QC lab with high resolution LC-MS.
LC-MS method development and validation.
Thermo Fisher Scientific Vanquish HPLC coupled to Exploris 120 or ISQ mass spectrometers for accurate molecular weight, purity and sequence information
Additional test methods including UV-Vis spectrometer, Raman, GC and Endotoxin analysis.
Method development validation.
Supporting information for regulatory submissions.
These capabilities ensure compliance with stringent quality and regulatory standards.
GMP supply for preclinical and clinical studies
Secure high-quality oligonucleotides for early-stage development:
Scalable oligonucleotide production for gram scale (1–30 mmol) for pre-clinical studies.
Clinical-grade oligonucleotide synthesis at kg scale (10–100 mmol).
Cytiva’s OligoPilotTM, ÄktaprocessTM and UnifluxTM with supporting process equipment.
Electronic batch record and dedicated process transfer support
Seamless integration with supply chain partners for formulation development and drug product manufacturing.
Evaluation and integration of new process technologies including biocatalytic, liquid phase and fragment-based synthesis.
Full package of quality assurance services, including ‘Qualified Person’.
These capabilities support regulatory compliance and enable smooth progression from discovery to clinical trials.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
What we offer
Whether you need technical expertise, lab-based development, process optimisation, or regulatory guidance, our tailored approach ensures you have the right support at every stage.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
Oligonucleotide process development and scale-up
Optimise and scale your oligonucleotide therapeutics with CPI’s expertise:
Synthesis of DNA, RNA, and modified oligonucleotides.
Optimisation of reaction conditions for enhanced yield and purity.
Enzymatic and chemical oligonucleotide synthesis technologies.
Downstream purification via anion exchange chromatography and ultrafiltration.
Techno-economic evaluation of novel synthesis and purification strategies
Process development from milligram to gram-scale.
Process equipment including Cytiva’s OligoSyntTM, Äkta FluxTM, and Äkta PureTM.
These capabilities ensure cost-effective, scalable oligonucleotide manufacturing.
Oligonucleotide analytical development and characterisation
Ensure the quality, integrity, and stability of your oligonucleotide-based therapeutics with CPI’s analytical expertise:
Purity analysis in our on-site QC lab with high resolution LC-MS.
LC-MS method development and validation.
Thermo Fisher Scientific Vanquish HPLC coupled to Exploris 120 or ISQ mass spectrometers for accurate molecular weight, purity and sequence information
Additional test methods including UV-Vis spectrometer, Raman, GC and Endotoxin analysis.
Method development validation.
Supporting information for regulatory submissions.
These capabilities ensure compliance with stringent quality and regulatory standards.
GMP supply for preclinical and clinical studies
Secure high-quality oligonucleotides for early-stage development:
Scalable oligonucleotide production for gram scale (1–30 mmol) for pre-clinical studies.
Clinical-grade oligonucleotide synthesis at kg scale (10–100 mmol).
Cytiva’s OligoPilotTM, ÄktaprocessTM and UnifluxTM with supporting process equipment.
Electronic batch record and dedicated process transfer support
Seamless integration with supply chain partners for formulation development and drug product manufacturing.
Evaluation and integration of new process technologies including biocatalytic, liquid phase and fragment-based synthesis.
Full package of quality assurance services, including ‘Qualified Person’.
These capabilities support regulatory compliance and enable smooth progression from discovery to clinical trials.
Oligonucleotides
applications
We enable innovation across a wide range of oligonucleotide and RNA therapeutics, including gene silencing and modulation treatments.
Antisense oligonucleotides.
siRNA and miRNA therapies.
Aptamer-based drugs.
Oligonucleotide conjugates.
How we support you
From discovery to commercialisation, we enable scalable, cost-effective, and regulatory-compliant pharmaceutical innovations.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
Demonstrate the benefits of your oligonucleotide innovation
Leverage our expertise to accelerate early-stage development and build investor confidence with:
Fast, cost-effective oligonucleotide process development to support funding and investment.
Demonstration of oligonucleotide processes in industry-relevant settings.
Prove manufacturability and scalability
Ensure your oligonucleotide therapies are reproducible and scalable with our advanced processing expertise. With CPI, you can access:
Early-stage manufacturability assessments for oligonucleotide production.
Process optimisation for yield, stability, and cost-effectiveness.
Scalable synthesis and purification methods for clinical readiness.
Assess and demonstrate commercial viability
We provide data-driven insights and process validation to secure investment and commercial partnerships. We support with:
Commercial feasibility assessments for oligonucleotide-based therapeutics.
Industrialisation of scale-up processes to secure funding or licensing deals.
Transitioning from preclinical development to commercial production.
Secure strategic partnerships
As a trusted UK Government partner, we have built a broad network across global leaders, emerging companies, large corporates, healthcare, and academia. We help you to:
Access our network of world-class oligonucleotide manufacturers, academic partners, and support for regulatory, upstream and downstream.
Build robust supply chains for oligonucleotide drug production.
Collaborate on industry-wide oligonucleotide innovation challenges.
How we support you
From discovery to commercialisation, we enable scalable, cost-effective, and regulatory-compliant pharmaceutical innovations.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
Demonstrate the benefits of your oligonucleotide innovation
Leverage our expertise to accelerate early-stage development and build investor confidence with:
Fast, cost-effective oligonucleotide process development to support funding and investment.
Demonstration of oligonucleotide processes in industry-relevant settings.
Prove manufacturability and scalability
Ensure your oligonucleotide therapies are reproducible and scalable with our advanced processing expertise. With CPI, you can access:
Early-stage manufacturability assessments for oligonucleotide production.
Process optimisation for yield, stability, and cost-effectiveness.
Scalable synthesis and purification methods for clinical readiness.
Assess and demonstrate commercial viability
We provide data-driven insights and process validation to secure investment and commercial partnerships. We support with:
Commercial feasibility assessments for oligonucleotide-based therapeutics.
Industrialisation of scale-up processes to secure funding or licensing deals.
Transitioning from preclinical development to commercial production.
Secure strategic partnerships
As a trusted UK Government partner, we have built a broad network across global leaders, emerging companies, large corporates, healthcare, and academia. We help you to:
Access our network of world-class oligonucleotide manufacturers, academic partners, and support for regulatory, upstream and downstream.
Build robust supply chains for oligonucleotide drug production.
Collaborate on industry-wide oligonucleotide innovation challenges.
How we support you
From discovery to commercialisation, we enable scalable, cost-effective, and regulatory-compliant pharmaceutical innovations.
Demonstrate the benefits of your oligonucleotide innovation
Leverage our expertise to accelerate early-stage development and build investor confidence with:
Fast, cost-effective oligonucleotide process development to support funding and investment.
Demonstration of oligonucleotide processes in industry-relevant settings.
Prove manufacturability and scalability
Ensure your oligonucleotide therapies are reproducible and scalable with our advanced processing expertise. With CPI, you can access:
Early-stage manufacturability assessments for oligonucleotide production.
Process optimisation for yield, stability, and cost-effectiveness.
Scalable synthesis and purification methods for clinical readiness.
Assess and demonstrate commercial viability
We provide data-driven insights and process validation to secure investment and commercial partnerships. We support with:
Commercial feasibility assessments for oligonucleotide-based therapeutics.
Industrialisation of scale-up processes to secure funding or licensing deals.
Transitioning from preclinical development to commercial production.
Secure strategic partnerships
As a trusted UK Government partner, we have built a broad network across global leaders, emerging companies, large corporates, healthcare, and academia. We help you to:
Access our network of world-class oligonucleotide manufacturers, academic partners, and support for regulatory, upstream and downstream.
Build robust supply chains for oligonucleotide drug production.
Collaborate on industry-wide oligonucleotide innovation challenges.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
How we support you
From discovery to commercialisation, we enable scalable, cost-effective, and regulatory-compliant pharmaceutical innovations.
Demonstrate the benefits of your oligonucleotide innovation
Leverage our expertise to accelerate early-stage development and build investor confidence with:
Fast, cost-effective oligonucleotide process development to support funding and investment.
Demonstration of oligonucleotide processes in industry-relevant settings.
Prove manufacturability and scalability
Ensure your oligonucleotide therapies are reproducible and scalable with our advanced processing expertise. With CPI, you can access:
Early-stage manufacturability assessments for oligonucleotide production.
Process optimisation for yield, stability, and cost-effectiveness.
Scalable synthesis and purification methods for clinical readiness.
Assess and demonstrate commercial viability
We provide data-driven insights and process validation to secure investment and commercial partnerships. We support with:
Commercial feasibility assessments for oligonucleotide-based therapeutics.
Industrialisation of scale-up processes to secure funding or licensing deals.
Transitioning from preclinical development to commercial production.
Secure strategic partnerships
As a trusted UK Government partner, we have built a broad network across global leaders, emerging companies, large corporates, healthcare, and academia. We help you to:
Access our network of world-class oligonucleotide manufacturers, academic partners, and support for regulatory, upstream and downstream.
Build robust supply chains for oligonucleotide drug production.
Collaborate on industry-wide oligonucleotide innovation challenges.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
We are over 500 world-class innovation experts, scientists and engineers.
We are over 500 world-class innovation experts, scientists and engineers.
We are over 500 world-class innovation experts, scientists and engineers.
£3 billion of private investment unlocked
R&D projects delivered
Years of experience
Business collaborations
m² of facilities
Over £220m of innovation assets
£3 billion of private investment unlocked
R&D projects delivered
Years of experience
Business collaborations
m² of facilities
Over £220m of innovation assets
£3 billion of private investment unlocked
R&D projects delivered
Years of experience
Business collaborations
m² of facilities
Over £220m of innovation assets
Trusted by leading organisations
,
Why choose CPI?
Work with us to defer capital and workforce investments until your product or process is proven at scale.
Oligonucleotide expertise
Proven success in synthesis, purification, and scale-up.
Industry-leading infrastructure
Supporting full-scale oligonucleotide manufacturing, with our Oligonucleotide Manufacturing Innovation Centre of Excellence.
Collaborative approach
We connect you with industry partners, funding opportunities, and regulatory insights to de-risk your journey.
End-to-end support
From early-stage development to clinical trials.
Get in touch
Let's innovate together
At CPI, we understand that every innovation, manufacturing process, and application is unique. Our flexible engagement model builds custom projects around your goals.
Barrie Cassey
Oligonucleotides
Business Development
Get in touch
Let's innovate together
At CPI, we understand that every innovation, manufacturing process, and application is unique. Our flexible engagement model builds custom projects around your goals.
Barrie Cassey
Oligonucleotides
Business Development
Get in touch
Let's innovate together
At CPI, we understand that every innovation, manufacturing process, and application is unique. Our flexible engagement model builds custom projects around your goals.
Barrie Cassey
Oligonucleotides
Business Development
